Terms: = Leukemia AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Clinical Outcome
27 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Genetic Polymorphism Study of idh 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract] [Full Text] [Related]
3. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and idh1/2 mutations.
Yasuda T; Sanada M; Kawazu M; Kojima S; Tsuzuki S; Ueno H; Iwamoto E; Iijima-Yamashita Y; Yamada T; Kanamori T; Nishimura R; Kuwatsuka Y; Takada S; Tanaka M; Ota S; Dobashi N; Yamazaki E; Hirose A; Murayama T; Sumi M; Sato S; Tange N; Nakamura Y; Katsuoka Y; Sakaida E; Kawamata T; Iida H; Shiraishi Y; Nannya Y; Ogawa S; Taniwaki M; Asou N; Hatta Y; Kiyoi H; Matsumura I; Horibe K; Mano H; Naoe T; Miyazaki Y; Hayakawa F
Blood; 2022 Mar; 139(12):1850-1862. PubMed ID: 34695176
[TBL] [Abstract] [Full Text] [Related]
4. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
[TBL] [Abstract] [Full Text] [Related]
5. Allogeneic Hematopoietic Cell Transplantation outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.
Salhotra A; Afkhami M; Yang D; Mokhtari S; Telatar M; Gu D; Pillai RK; Weisenburger DD; Murata-Collins J; Weigel D; Aoun P; Aldoss I; Al Malki MM; Khaled S; Mei M; Ali H; Aribi A; Budde E; Sandhu K; O'Donnell M; Snyder D; Pullarkat V; Forman SJ; Marcucci G; Nakamura R; Stein A
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e400-e405. PubMed ID: 31155409
[TBL] [Abstract] [Full Text] [Related]
6. The risk and clinical outcome of candidemia depending on underlying malignancy.
Lortholary O; Renaudat C; Sitbon K; Desnos-Ollivier M; Bretagne S; Dromer F;
Intensive Care Med; 2017 May; 43(5):652-662. PubMed ID: 28321466
[TBL] [Abstract] [Full Text] [Related]
7. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract] [Full Text] [Related]
8. Mutant idh: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.
Garrett-Bakelman FE; Melnick AM
Epigenomics; 2016 Jul; 8(7):945-57. PubMed ID: 27431380
[TBL] [Abstract] [Full Text] [Related]
9. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics, clinical outcome, and prognostic significance of idh mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract] [Full Text] [Related]
11. idh1, lipid metabolism and cancer: Shedding new light on old ideas.
Bogdanovic E
Biochim Biophys Acta; 2015 Sep; 1850(9):1781-5. PubMed ID: 25960387
[TBL] [Abstract] [Full Text] [Related]
12. High idh1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
[TBL] [Abstract] [Full Text] [Related]
13. idh mutation in glioma: new insights and promises for the future.
Turkalp Z; Karamchandani J; Das S
JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
[TBL] [Abstract] [Full Text] [Related]
14. clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A; Abdelali RB; Chevret S; Nibourel O; Cheok M; Pautas C; Duléry R; Boyer T; Cayuela JM; Hayette S; Raffoux E; Farhat H; Boissel N; Terre C; Dombret H; Castaigne S; Preudhomme C
Oncotarget; 2014 Feb; 5(4):916-32. PubMed ID: 24659740
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of idh1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
[TBL] [Abstract] [Full Text] [Related]
16. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract] [Full Text] [Related]
17. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract] [Full Text] [Related]
18. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
[TBL] [Abstract] [Full Text] [Related]
19. Isocitrate dehydrogenase mutations in leukemia.
McKenney AS; Levine RL
J Clin Invest; 2013 Sep; 123(9):3672-7. PubMed ID: 23999441
[TBL] [Abstract] [Full Text] [Related]
20. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
[TBL] [Abstract] [Full Text] [Related]
[Next]
